Xiwu Lin
13 Papers
3 Citations
Xiwu Lin is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 9 publications.
Chat about Author
Papers
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Maria-Victoria Mateos,Ajai Chari,Saad Z. Usmani,Hartmut Goldschmidt,Katja Weisel,Keqin Qi,Anil Londhe,Sandhya Nair,Xiwu Lin,Lixia Pei,Eric A. Ammann,Rachel Kobos,Jennifer Smit,Trilok V. Parekh,A. Marshall,Mary Slavcev,Philippe Moreau +16 more
TL;DR: In this paper , the efficacy and safety of teclistamab in patients with RRMM who received ≥3 prior lines of therapy and were triple-class exposed (TCE) are evaluated in the single-arm, multicohort, phase I/II MajesTEC-1 trial (NCT04557098).
4
Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
Amrita Krishnan,Ajay K. Nooka,Ajai Chari,Alfred L. Garfall,Thomas R. Martin,Sandhya Nair,Xiwu Lin,Keqin Qi,Anil Londhe,Lixia Pei,Eric A. Ammann,Rachel Kobos,Jennifer Smit,Trilok V. Parekh,Mary Slavcev,Saad Z. Usmani +15 more
TL;DR: Patients treated with teclistamab showed improved effectiveness for PFS, TTNT, and OS, compared with real-world treatments used in patients with TCE RRMM who received ≥3 prior LOT.
3
Peer Review
Estimands in Real-World Evidence Studies
Jie Chen,Daniel O. Scharfstein,Hongwei Wang,Binbing Yu,Yang Song,Weili He,John Scott,Xiwu Lin,Hana Lee +8 more
- 01 Jul 2023
TL;DR: In this paper , the authors present the essential components of estimands and causal inference framework, discusses the considerations in constructing estimands for RWE studies, highlights similarities and differences in traditional clinical trial and RWE study estimands, and provides a roadmap for choosing appropriate estimands.
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
Amrita Krishnan,Ajay K. Nooka,Ajai Chari,Alfred L. Garfall,Thomas R. Martin,Sandhya Nair,Xiwu Lin,Keqin Qi,Anil Londhe,Lixia Pei,Eric A. Ammann,Rachel Kobos,Jennifer Smit,Trilok V. Parekh,A. Marshall,Mary Slavcev,Saad Usmani +16 more
TL;DR: In this article , the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma was compared.
3